Cumberland Pharmaceuticals Files 8-K
Ticker: CPIX · Form: 8-K · Filed: Mar 20, 2024 · CIK: 1087294
Sentiment: neutral
Topics: regulatory-filing, 8-K
Related Tickers: CPRX
TL;DR
CPRX filed an 8-K, mostly procedural, no new info.
AI Summary
Cumberland Pharmaceuticals Inc. filed an 8-K on March 20, 2024, to report other events and file financial statements and exhibits. The filing does not contain specific financial figures or details about the nature of the "other events" beyond its procedural nature.
Why It Matters
This filing indicates Cumberland Pharmaceuticals is making a required regulatory submission, but it does not provide new operational or financial information that would typically impact investors.
Risk Assessment
Risk Level: low — The filing is a standard procedural 8-K and does not contain any new material information that would pose a risk to investors.
Key Players & Entities
- CUMBERLAND PHARMACEUTICALS INC (company) — Registrant
- 20240320 (date) — Filing Date
FAQ
What is the primary purpose of this 8-K filing for Cumberland Pharmaceuticals Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and to file 'Financial Statements and Exhibits' as required by the SEC.
On what date was this 8-K filed?
This 8-K was filed on March 20, 2024.
What is the principal executive office address for Cumberland Pharmaceuticals Inc.?
The principal executive office address is 1600 West End Avenue, Suite 1300, Nashville, Tennessee 37203.
What is the SIC code for Cumberland Pharmaceuticals Inc.?
The Standard Industrial Classification (SIC) code for Cumberland Pharmaceuticals Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Does this filing provide specific details about the 'Other Events' or financial performance?
No, this filing is a procedural 8-K and does not provide specific details about the 'Other Events' or new financial performance figures.
Filing Stats: 1,430 words · 6 min read · ~5 pages · Grade level 12.9 · Accepted 2024-03-20 17:20:34
Key Financial Figures
- $5,800,000 — , as sales agent or principal, of up to $5,800,000 of shares of the Company's common stock
Filing Documents
- cpix-20240320.htm (8-K) — 37KB
- exhibit11salesagreement.htm (EX-1.1) — 292KB
- exhibit51opinion.htm (EX-5.1) — 19KB
- image_01a.jpg (GRAPHIC) — 272KB
- image_0a.jpg (GRAPHIC) — 0KB
- image_2a.jpg (GRAPHIC) — 0KB
- image_4a.jpg (GRAPHIC) — 0KB
- 0001628280-24-012261.txt ( ) — 908KB
- cpix-20240320.xsd (EX-101.SCH) — 2KB
- cpix-20240320_lab.xml (EX-101.LAB) — 21KB
- cpix-20240320_pre.xml (EX-101.PRE) — 12KB
- cpix-20240320_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. At-the-Market Offering Program On March 20, 2024, Cumberland Pharmaceuticals Inc. (the "Company") filed a prospectus supplement with the Securities and Exchange Commission (the "SEC") in connection with the Company's "at-the-market" offering program (the "ATM Offering") for the offer and sale from time to time through or to H.C. Wainwright & Co., LLC (the "Sales Agent"), as sales agent or principal, of up to $5,800,000 of shares of the Company's common stock, no par value per share (the "Shares"), pursuant to the Company's Sales Agreement with the Sales Agent dated March 20, 2024 (the "Sales Agreement"). The Shares are being offered and sold pursuant to the Company's shelf registration statement on Form S-3 (the "Shelf Registration Statement") filed with the SEC on December 14, 2023, which became effective upon the notice of effectiveness filed December 26, 2023 (File No. 333-276052). From time to time during the term of the Sales Agreement, the Company may deliver a placement notice to the Sales Agent specifying the length of the selling period, the amount of Shares to be sold, any limitation on the number of shares that may be sold in any one trading day and the minimum price below which sales may not be made. Pursuant to the Sales Agreement and upon its acceptance of a placement notice from the Company, the Sales Agent may sell the Shares, by any method permitted by law deemed to be an "at the market offering" as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the "Securities Act"). The Company may instruct the Sales Agent not to sell Shares if the sales cannot be effected at or above the price designated by the Company in any placement notice. The Company or the Sales Agent may suspend the ATM Offering at any time upon proper notice and subject to other conditions. The Company will pay the Sales Agent a commission for its services in acting as agent in the sale of Shares. The Sales Agent will be entitled to co
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Sales Agreement, dated March 20, 2024, by and between Cumberland Pharmaceuticals Inc. and H.C. Wainwright & Co., LLC. 5.1 Opinion of Baker, Donelson, Bearman, Caldwell & Berkowitz, PC. 23.1 Consent of Baker, Donelson, Bearman, Caldwell & Berkowitz, PC (contained in Exhibit 5.1 above). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cumberland Pharmaceuticals Inc. Dated: March 20, 2024 By: /s/ A.J. Kazimi A.J. Kazimi Chief Executive Officer